Close Menu

NEW YORK (360Dx) – Laboratory Corporation of American said this week that its Covance Drug Development segment will buy Envigo's nonclinical research services business, while Envigo's Research Models Services business will buy LabCorp's Covance Research Products business in a $485 million deal to be paid by LabCorp. The deal allows Covance to expand its global nonclinical drug development capabilities, and Envigo will become a pure-play research models and services business.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.